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; accepted July 13, 2013.rates during the 1990s and early 2000s (4,5), consistent with
ﬁndings from Europe (3,6). Recent advances in medical care
could impact endocarditis hospitalizations and outcomes.
Whereas historical risk factors such as rheumatic heart
disease have declined (2,7–9), increased use and longevity of
recipients of devices such as prosthetic heart valves, perma-
nent pacemakers, cardiac-resynchronization therapy, and
implantable cardioverter deﬁbrillators have potentially
increased the number of patients at risk of endocarditis
(4,10–12). Furthermore, in May 2007, indications for anti-
biotic prophylaxis were markedly narrowed by the American
Heart Association to certain high-risk subgroups undergoing
dental procedures (8), potentially increasing the risk of
endocarditis in vulnerable patients (13).
Little is known about more recent national trends in
endocarditis hospitalizations and outcomes among older
adults, a growing population who may be at disproportion-
ately high risk of developing and dying from endocarditis
(2,14,15). Therefore, we sought to assess the annual rates
of hospitalization with endocarditis from 1999 through
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and Acronyms
AHA = American Heart
Association
CI = conﬁdence interval
CVD = cerebrovascular
disease
ICD-9-CM = International
Classiﬁcation of Diseases-
Ninth Revision-Clinical
Modiﬁcation
ICF = intermediate care
facility
SNF = skilled nursing facility
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22182010 among all Medicare fee-
for-service beneﬁciaries age 65
years in the United States. We
also investigated trends in the
rates of hospitalization for en-
docarditis and in outcomes across
demographic subgroups.Methods
Data source. Using the Centers
for Medicare & Medicaid Ser-
vices Medicare inpatient Stan-
dard Analytic Files, we analyzed
all inpatient admissions of fee-for-service beneﬁciaries age 65 years from 1999 to 2010.
We included patients who had participated for at least 1
month in fee-for-service and resided or were hospitalized in
theUnited States.Medicare inpatient StandardAnalytic Files
contain patient demographics and procedural and diagnostic
information for hospitalizations based on the International
Classiﬁcation of Diseases-Ninth Revision-, Clinical Modi-
ﬁcation (ICD-9-CM), as well as dates of hospital admission
and discharge disposition. We used Denominator Files from
1999 to 2010 to determine beneﬁciaries’ eligibility and
enrollment in Medicare and used a single beneﬁciary in
a single year as the unit of observation. We determined death
through the Centers for Medicare &Medicaid Services Vital
Status File, which includes information on out-of-hospital
mortality. This study was exempt from additional review by
the Human Investigation Committee at Yale University
because all data were de-identiﬁed.
Patient population. Patients with a principal or secondary
ICD-9-CM discharge diagnosis of endocarditis were
included using the following codes: 421.0 (acute and
subacute infective endocarditis), 421.1 (endocarditis, valve
unspeciﬁed, in diseases classiﬁed elsewhere), 421.9 (acute
endocarditis, unspeciﬁed), and 424.9 (endocarditis, valve
unspeciﬁed). These codes have been frequently used in
previous studies of endocarditis (3–5,13,16). We excluded
patients with a principal or secondary discharge diagnosis of
infection or inﬂammation of intracardiac devices (996.61)
because the population of older adults who receive intracar-
diac devices has been increasing over time (17) and it was not
possible to deﬁne a denominator of all patients who had
a device in order to calculate a rate. Nevertheless, we repeated
our analysis without excluding these patients to determine if
the results changed substantively. In addition, we examined
hospitalizations for endocarditis and outcomes in the subset
of patients with only a principal discharge diagnosis of
endocarditis. For patients who had multiple hospitalizations
for endocarditis in a given year (18%), we selected a random
hospitalization because we were interested in the patient as
the unit of analysis.
Patient characteristics and comorbidities. We examined
the demographic and clinical characteristics of patientshospitalized with endocarditis. We determined patient-
reported race from the Medicare Denominator File. We
used comorbidities in the models employed by the Centers
for Medicare & Medicaid Services to proﬁle hospital 30-day
mortality measures for cardiovascular conditions (18,19).
They were identiﬁed from secondary diagnosis codes (which
did not represent a potential complication) recorded at the
time of discharge from the hospitalization for endocarditis,
as well as the primary or secondary diagnosis codes of all
inpatient stays up to 1 year before the index hospitalization.
Outcome measures. For each year, we calculated the rate
of hospitalization for endocarditis. The numerator included
all patients discharged with endocarditis in a given year. We
calculated the denominator using the total number of
months that fee-for-service beneﬁciaries were enrolled or at
risk during the year to account for new enrollment, disen-
rollment, or death, converted to person-years. All rates are
reported per 100,000 person-years.
Among patients hospitalized with endocarditis, we
determined the annual rates of in-hospital, 30-day, 6-month,
and 1-year all-cause mortality. We used the date of admis-
sion as the “time zero” for all mortality measures. In addition,
we examined trends in hospital length of stay, deﬁned as
the difference between the discharge and admission dates.
Statistical analysis. We used the Mantel-Haenszel chi-
square test to determine the signiﬁcance of temporal changes
in the rates of hospitalization for endocarditis and mortality.
In addition to overall results, we stratiﬁed trends in the rates
of hospitalization and outcomes by age (65 to 74 years, 75 to
84 years, and 85 years), sex, and race (white, black, and
other).
We ﬁtted a linear mixed-effects model with a Poisson link
function and state-speciﬁc random intercepts to assess
annual rates of hospitalization for endocarditis adjusted for
age, sex, and race. We considered the rate of hospitalization
for endocarditis during 1999 as the referent and calculated
the incidence rate ratio for each subsequent year by including
indicator variables for the subsequent years in the mixed-
effects model.
To obtain annual mortality rates adjusted for patient
demographics and comorbidities, we ﬁtted a linear mixed-
effects model with a logit link function and state-speciﬁc
random intercepts. Using data from 1999 as the referent
and indicator variables for each subsequent year, we calcu-
lated the risk-adjusted odds ratios for mortality for subse-
quent years. Using the method described by Zhang and Yu
(20), we converted the odds ratio values to risk ratio esti-
mates. We then multiplied the risk ratio for each year by the
mortality rate in the baseline year (i.e., 1999) to calculate the
adjusted mortality rates across years.
As a secondary objective, we compared the rates of
hospitalization for endocarditis and mortality before and
after 2007, when the American Heart Association narrowed
the indications for antibiotic prophylaxis for endocarditis. A
possible increase in endocarditis hospitalization rates or
worsening of outcomes in recent years, if they exist, could be
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2219attributable to many factors, including change in the clinical
comorbidities and underlying conditions that predispose to
endocarditis, in addition to the changes in the guidelines.
However, we assumed that such an increase would be an
important safety signal warranting further surveillance in-
vestigation. To compare the hospitalization rates and
outcomes before and after 2007, we used separate mixed-
effects models similar to those described above but with
2007 as the reference. We also calculated a 95% conﬁdence
interval (CI) for each point estimate from the models.
All analyses were performed with SAS, version 9.3 64-bit
(SAS Institute, Cary, North Carolina). A p value <0.05 was
considered signiﬁcant, and all tests were 2-sided. The
funding source had no role in the study design, analysis,
interpretation, or submission of the results.Results
Overall, 262,658 patients age 65 years were hospitalized
with endocarditis between 1999 and 2010 in the fee-for-
service population (Table 1). The mean age of patientsTable 1 Characteristics of Patients Hospitalized With Infective Endo
1999–2000 2001–2002
No. of patients with endocarditis 38,671 43,795
Age, yrs 79.4  8.0 79.3  8.0
Female 58.8 58.8
Race
White 87.1 87.1
Black 9.2 9.2
Other 3.7 3.7
CV risk factors and history
Hypertension 48.2 52.7
Diabetes mellitus 25.8 27.3
History of
Atherosclerotic disease 41.6 43.2
Myocardial infarction 4.5 5.1
Unstable angina 4.9 4.6
Peripheral vascular disease 10.2 10.8
Heart failure 32.4 32.9
Stroke 4.0 3.7
CVD other than stroke 7.1 7.3
History of other clinical conditions/comorbidities
Cancer 11.6 11.7
Chronic obstructive pulmonary disease 25.3 27.0
Pneumonia 17.3 18.3
Respiratory failure 5.6 6.0
Renal failure 11.4 13.4
Liver disease 2.1 2.1
Malnutrition 7.4 7.6
Depression 6.1 7.1
Other psychiatric disorder 2.7 2.8
Dementia 10.9 11.7
Functional disability 4.3 4.1
Trauma 9.0 10.0
Values are n, mean  SD, or %.
CVD ¼ cerebrovascular disease.was similar over time (79.2 to 79.4 years). The proportion of
female patients declined from 58.8% to 55.7% (p ¼ 0.002
for trend), whereas the proportion of black patients increased
from 9.2% to 10.0% (p ¼ 0.02 for trend). Some comor-
bidities were more frequently coded over time, including
history of hypertension (48.2% to 58.9%; p ¼ 0.003
for trend) and history of renal failure (11.4% to 29.2%;
p < 0.001 for trend).
Hospitalizations. The adjusted rate of hospitalizations for
endocarditis was 72.0 per 100,000 person-years in 1999. It
increased gradually to 83.5 per 100,000 person-years in 2005
and declined thereafter (Fig. 1, Table 2). In particular, the
rate of hospitalizations in which endocarditis was the prin-
cipal or secondary diagnosis declined consistently after 2007
(incidence rate ratios: 0.97 [95% CI: 0.94 to 0.99], 0.91
[95% CI: 0.89 to 0.93], and 0.86 [95% CI: 0.84 to 0.88] for
2008, 2009, and 2010, respectively, compared with 2007).
Among all patients with infective endocarditis from 1999
to 2010, 52,145 had a principal discharge diagnosis of
endocarditis. The adjusted hospitalization rate in this
subgroup declined from 17.0 per 100,000 person-years incarditis in Medicare Fee-for-Service, 1999 to 2010
2003–2004 2005–2006 2007–2008 2009–2010
47,820 47,860 44,761 39,751
79.2  8.2 79.2  8.3 79.4  8.6 79.2  8.8
58.1 57.7 56.9 55.7
86.5 86.6 86.3 85.7
9.7 9.5 9.6 10.0
3.8 3.9 4.1 4.2
54.7 54.8 59.1 58.9
28.6 29.1 28.8 29.7
43.6 42.8 41.8 40.3
5.3 5.2 5.5 5.8
3.9 3.3 2.9 2.7
11.6 11.7 12.5 12.4
34.1 34.2 33.9 34.1
3.9 3.9 4.1 4.1
6.8 5.8 6.0 5.7
11.8 11.3 11.8 11.8
28.4 29.7 28.0 24.5
19.4 20.6 23.3 25.7
6.7 8.1 11.3 12.3
15.9 20.0 25.2 29.2
2.4 2.2 2.2 2.3
8.4 8.8 11.3 14.1
7.9 7.4 7.3 6.8
2.7 2.4 2.9 3.2
11.7 11.9 12.8 13.2
4.1 3.8 4.3 4.7
10.9 10.8 11.2 10.6
Figure 1 Hospitalization Rates for Infective Endocarditis in Medicare Fee-For-Service Beneﬁciaries, 1999 to 2010
Circles and diamonds denote observed values; lines represent smoothed trends over time. The solid line indicates principal or secondary diagnosis codes; the dashed line
indicates principal diagnosis code only. AHA ¼ American Heart Association.
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22201999 to 11.2 per 100,000 person-years in 2010 (p < 0.001
for trend) (Fig. 1, Table 2). The rate of hospitalizations for
endocarditis for these patients also consistently declined
after 2007 (incidence rate ratios: 0.94 [95% CI: 0.90 to
0.98], 0.89 [95% CI: 0.84 to 0.93], and 0.81 [95% CI: 0.77
to 0.85] for 2008, 2009, and 2010, respectively).
Mortality. In-hospital mortality rates declined from 11.1%
in 1999 to 9.1% in 2010 (p < 0.001 for trend). From 1999
to 2010, adjusted 30-day mortality rates ranged from 14.2%
to 16.5%. Adjusted 6-month mortality rates ranged from
28.4% to 31.8%. Across the years, 1-year mortality rates
were fairly close to 6-month mortality rates and ranged from
32.6% to 36.2% (Table 2). Except for 2006, adjusted rates
of 30-day, 6-month, and 1-year mortality were lowest
during 2007. Mortality at 30 days and 1 year appeared to
increase slightly during 2008 compared with 2007 (odds
ratios: 1.08 [95% CI: 1.03 to 1.14] and 1.05 [95% CI: 1.009
to 1.09], respectively); however, the increased mortality was
inconsistent and became nonsigniﬁcant during 2009 (odds
ratios: 1.04 [95% CI: 0.99 to 1.10] and 1.006 [95% CI: 0.96
to 1.04], respectively) (Fig. 2A).
Among the subgroup with a principal discharge diagnosis
of endocarditis from 1999 to 2010, 30-day and 1-year
mortality rates ranged from 14.3% to 20.6% and from
33.7% to 41.4%, respectively. There was a trend toward
reduced adjusted 30-day and 1-year mortality rates after
2007 (Fig. 2B).
Length of stay and discharge disposition. From 1999 to
2010, the mean length of stay for hospitalizations for
endocarditis consistently declined, from 9.6  11.5 days to
8.4  8.9 days (p < 0.001 for trend). During that period,
there was a reduction in the proportion of discharges tohome (40.0% to 27.6%; p < 0.001 for trend) and an increase
in the proportion of patients discharged to home with home
health care or discharged to hospice (11.7% to 16.7% and
0.2% to 4.6%, respectively; p < 0.001 for trend for both
comparisons).
Hospitalization and mortality rates by age, sex, and race.
Across all age, sex, and race subgroups, rates of hospitalization
for endocarditis increased from 1999 to 2005, declined
slightly during 2006 to 2007, and continued to decline during
2008 to 2010 (Table 3). Stratiﬁed trends in the risk-adjusted
rates of 30-day, 6-month, and 1-year mortality were consis-
tent with those of the overall cohort. All results were
substantively similar when device-related hospitalizations
were included in the analyses (data not shown).Discussion
Our study demonstrated the high burden of endocarditis
among older adult fee-for-service Medicare beneﬁciaries.
The rates of 30-day, 6-month, and 1-year mortality
remained consistently high (approximately 15%, 30%, and
35%, respectively), similar to those found in previous studies
(2,3,21). We did not observe an increase in rates of hospi-
talization or mortality with endocarditis in more recent
years. In fact, rates of hospitalization for endocarditis
declined across all age, sex, and race subgroups from 2006
to 2007 and continued to do so from 2008 to 2010. Among
the subgroup with a principal discharge diagnosis of en-
docarditis, rates of hospitalization and mortality showed
a declining trend throughout the study period.
The annual endocarditis hospitalization rates that we ob-
served among older adults age 65 years with fee-for-service
Table 2 Hospitalizations and Outcomes of Infective Endocarditis in Medicare Fee-for-Service Beneﬁciaries, 1999 to 2010
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Denominator, person-yrs 26,479,079 26,768,087 27,553,904 28,345,999 28,821,487 29,109,293 29,157,293 28,452,501 27,899,732 27,675,586 27,343,436 27,696,576
Adjusted* endocarditis (principal
or secondary diagnosis)
hospitalization rate per
100,000 person-yrs
72.0 73.4
(72.0–75.6)
77.8
(75.6–79.2)
79.2
(77.8–81.4)
82.1
(79.9–84.2)
83.5
(81.4–85.0)
83.5
(82.1–85.7)
82.1
(79.9–84.2)
81.4
(79.9–83.5)
79.2
(77.0–81.4)
74.9
(72.7–76.3)
70.6
(69.1–72.0)
Adjusted* endocarditis (principal
diagnosis) hospitalization rate
per 100,000 person-yrs
17.0 16.8
(16.2–17.5)
16.0
(15.3–16.7)
16.3
(15.6–17.0)
16.8
(16.2–17.6)
16.7
(16.0–17.3)
15.5
(14.8–16.2)
15.1
(14.5–15.8)
13.9
(13.3–14.5)
13.1
(12.6–13.8)
12.2
(11.7–12.9)
11.2
(10.7–11.7)
Outcomes
Length of stay, days 9.6  11.5 9.3  11.4 9.3  11.0 9.3  10.9 9.1  10.5 8.8  10.7 8.7  10.4 8.5  9.8 8.4  9.2 8.7  10.4 8.5  9.9 8.4  8.9
In-hospital mortality, % 11.1
(10.6–11.5)
10.6
(10.2–11.1)
11.1
(10.7–11.5)
11.4
(11.0–11.8)
10.9
(10.5–11.3)
10.3
(9.90–10.7)
9.4
(9.0–9.8)
9.0
(8.6–9.4)
8.8
(8.4–9.2)
9.7
(9.3–10.1)
9.3
(8.9–9.7)
9.1
(8.8–9.6)
Adjusted 30-day mortality, %y 15.8
(15.3–16.3)
15.7
(15.0–16.5)
16.1
(15.4–16.9)
16.5
(15.8–17.2)
16.1
(15.3–16.7)
15.8
(15.1–16.6)
15.0
(14.3–15.7)
14.2
(13.5–14.9)
14.6
(13.9–15.3)
15.7
(15.0–16.3)
15.1
(14.4–15.8)
15.3
(14.6–16.1)
Adjusted 6-month mortality, %y 31.6
(30.9–32.2)
31.4
(30.5–32.5)
31.6
(30.7–32.7)
31.8
(30.7–32.7)
31.6
(30.7–32.7)
31.2
(30.3–32.2)
30.3
(29.4–31.4)
28.4
(27.7–29.4)
29.1
(28.2–30.1)
30.3
(29.4–31.2)
29.6
(28.5–30.5)
29.6
(28.5–30.7)
Adjusted 1-year mortality, %y 35.7
(35.1–36.4)
35.7
(34.8–36.6)
36.2
(35.2–37.0)
35.9
(35.0–36.8)
35.5
(34.5–36.4)
35.0
(34.1–36.2)
33.8
(33.3–34.8)
32.6
(31.5–33.3)
33.1
(32.3–34.1)
34.3
(33.3–35.2)
33.3
(32.3–34.3)
33.8
(32.8–34.8)
Discharge disposition
Home 40.0 40.7 40.1 38.8 37.0 34.9 34.6 34.2 32.4 30.8 29.9 27.6
Home health care 11.7 11.3 11.3 11.5 12.4 14.4 14.3 15.2 16.1 15.5 16.2 16.7
ICF/SNF 26.0 25.8 25.0 25.1 24.7 25.5 26.2 26.1 26.2 26.6 26.9 28
Hospice 0.2 0.3 0.6 1.0 1.5 2.1 2.5 3.1 3.5 4.0 4.4 4.6
Transferred out 5.3 5.3 5.2 4.5 4.5 4.3 4.3 3.8 4.0 4.0 3.7 4.0
Hospital death 11.1 10.6 11.1 11.4 10.9 10.3 9.4 9.0 8.8 9.7 9.3 9.1
Otherz 5.7 6.0 6.7 7.7 9.0 8.5 8.7 8.6 9.0 9.4 9.6 10.0
Values in parentheses are 95% conﬁdence intervals. *Adjusted for age, sex, and race (reference year: 1999). yAdjusted for age, sex, race, and clinical comorbidities (reference year: 1999). zIncluding discharge against medical advice.
ICF/SNF ¼ intermediate care facility/skilled nursing facility.
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Figure 2 Comparison of Rates of Hospitalization for Endocarditis and Outcomes
(A) Any listed endocarditis, and (B) principal discharge diagnosis of endocarditis. Data from 2007, the year of publication of the new American Heart Association guidelines,
were the reference. Adjusted incidence rate ratios (for hospitalizations) and odds ratios (for outcomes) were calculated for each year before and after 2007.
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2222coverage from 1999 to 2010 were higher than the rates
found in previous studies (22,23). A combination of younger
age, lower risk proﬁle, under-reporting in the previous
studies, and overcoding in our study may have contributed tothe differences. Over time, we observed slight declines in
hospital length of stay and rates of in-hospital mortality,
along with an increase in the proportion of patients dis-
charged to hospice or to home with healthcare assistance,
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2223a pattern that has been recognized (24). Patients age 85
years had higher rates of hospitalization and mortality
compared with those in other age groups, likely related to
their greater comorbidity burden and immunosenescence
(25). We also observed consistently higher rates of hospi-
talization and mortality among black patients. Although
some reports suggest ethnic differences in the incidence of
endocarditis (26–28), this topic has been largely understudied
in the United States (4,29).
We did not observe an increase in rates of hospitalization
for endocarditis or of mortality following the 2007 release of
more restrictive recommendations for prophylaxis by the
American Heart Association. Our analysis, however, was not
meant to be a comparative effectiveness study to prove the
noninferiority of more restrictive use of antibiotics for
endocarditis prophylaxis. National data regarding antibiotic
use after the publication of the 2007 American Heart
Association guidelines are not available. However, it is likely
that the guidelines have caused a decline in prophylactic use
of antibiotics. For example, a study from the United
Kingdom showed marked reduction in the use of prophy-
lactic antibiotics following the release of the guidelines for
endocarditis from the National Institute for Health and
Clinical Excellence (6). Similarly, results of recent surveys in
the United States suggest a decline in the use of antibiotic
prophylaxis for patients with non–high-risk cardiac condi-
tions (30,31).
The intent of our secondary analysis was to determine
whether the possible reduced use of antibiotics has been
associated with temporal changes in trends for hospitaliza-
tions or outcomes of endocarditis among older adults. If an
increase in endocarditis hospitalizations had occurred after
2007, it could have been due to a combination of more
widespread use of intracardiac and intravascular devices
(such as mechanical valves, pacemakers, and dialysis cathe-
ters) among older adults, a change in the pattern of
comorbidities, or restrictive antibiotic use, and this would
warrant further investigation. However, we did not observe
an increase in hospitalization rates after 2007, but rather
found a signiﬁcant decline in endocarditis hospitalization
rates that continued through 2007 to 2010.
Compared with 2007, the upper bound of the 95% CI for
adjusted hospitalization rates consistently remained below
1.0 for years 2008, 2009, and 2010. This lack of increased
hospitalization rates after 2007 could be due to several
reasons, including lack of a substantial effect for widespread
endocarditis prophylaxis, lack of penetrance of guideline
recommendations into widespread clinical practice change,
or pronounced change in endocarditis hospitalizations for
reasons that are not related to antibiotic prophylaxis. Irre-
spective of the magnitude of change in prophylactic antibi-
otic use and other risk factors, our current surveillance
investigation did not show a safety concern in terms of
increased number of hospitalizations. The decline that we
observed in endocarditis hospitalization rates warrants
further investigation and might be in part due to concertedstrategies that have been used to reduce the rates of catheter-
associated bloodstream infections (32).
Our ﬁndings are consistent with those of 3 other studies
that evaluated the incidence of endocarditis after publication
of the 2007 guidelines. In a single-center study, Rogers and
Schiller (13) did not ﬁnd an increase in the number of
hospitalizations for endocarditis during the ﬁrst 9 months
after publication of the guidelines. Similarly, Pasquali et al.
(33) did not ﬁnd an increase in the number of admissions for
endocarditis in their study of 37 children’s hospitals in the
United States. Desimone et al. (30) did not observe an
increase in hospitalization rates for patients with diagnosed
or suspected endocarditis caused by viridans streptococci
among residents of Olmsted County, Minnesota, after the
2007 guidelines were published. Using records from the
Nationwide Inpatient Sample, they also reported little
change after 2007 (30). That report, however, only reﬂected
endocarditis caused by viridans streptococci, did not include
hospitalization rates that accounted for changes in the
denominator, did not analyze demographic subgroups, and
extended only until 2009.
The impact of reduced antibiotic prophylaxis on the rates
of hospitalization for endocarditis has also been the topic of
international investigation. A study from the United
Kingdom found that although overall incidence of endo-
carditis rose from 2000 to 2010, the increase did not
accelerate after publication of the 2008 guidelines on
cessation of antibiotic prophylaxis from the National Insti-
tute for Health and Clinical Excellence (6). A study by
Duval et al. (22), conducted over 3 cross-sectional time
periods in France, did not ﬁnd major changes in the inci-
dence of endocarditis related to the change in the prophy-
laxis recommendations. Neither of these studies reported
outcomes such as 30-day or 1-year mortality.
Study strengths. Our study had several strengths. Our
study represents national data for endocarditis hospitaliza-
tions in the entire population of Medicare fee-for-service
older adults. Adjusted short-term and 1-year mortality
rates are also important and were not available from previous
studies that reported trends in hospitalizations with endo-
carditis. Consistent results across several subgroups and in
sensitivity analyses support the validity of the ﬁndings.
Study limitations. First, we studied the hospitalizations
and outcomes in older adults. However, we expect trends in
this high-risk group to be indicative of overall trends.
Second, we did not have access to data from beneﬁciaries in
the Medicare Advantage plans (approximately 10 million
beneﬁciaries in February 2009, or one-quarter of all
Medicare users) (34). Given that Medicare Advantage
patients are generally considered healthier (35), the growing
migration of (healthier) patients to Medicare Advantage
could have biased the trends toward showing increased
endocarditis hospitalization rates in recent years. Third,
although we analyzed data for 100% of fee-for-service
beneﬁciaries rather than a select cohort, and thus elimi-
nated referral bias (36), the use of administrative discharge
Table 3 Hospitalizations for Endocarditis and Outcomes by Age, Sex, and Race
1999 2000 2001 2002 2003 2004 2005 2006 2 2008 2009 2010
Adjusted* hospitalization rate per 100,000 person-years
Age, yrs
65–74 45.0 45.5 47.3 48.6 50.0 50.9 50.4 49.1 46.8 45.0 42.3
75–84 87.0 89.6 96.6 98.3 102.7 103.5 103.5 103.5 1 98.3 94.0 87.9
85 146.0 150.4 153.3 159.1 163.5 165.0 171.0 163.5 1 163.5 148.9 143.1
Sex
Female 70.0 72.8 77.0 78.4 81.2 83.3 83.3 81.2 77.7 72.8 68.6
Male 73.0 73.0 75.9 78.8 81.8 81.8 82.5 81.0 78.8 75.2 70.8
Race
Black 86.0 85.1 88.6 93.7 100.6 100.6 100.6 99.8 102.3 96.3 89.4
White 72.0 74.2 77.8 79.2 81.4 82.8 83.5 82.1 78.5 74.2 69.8
Other 47.0 51.2 46.5 52.6 49.8 52.6 52.2 48.9 48.9 45.6 42.3
Adjusted 30-day mortality rate, %y
Age, yrs
65–74 15.4
(14.5–16.4)
15.3
(13.9–16.7)
16.4
(15.1–17.9)
16.0
(14.7–17.4)
15.3
(14.1–16.7)
15.3
(14.1–16.6)
14.2
(13.0–15.4)
13.1
(12.0–14.3) (12. )
14.9
(13.7–16.2)
13.5
(12.4–14.9)
14.5
(13.3–15.8)
75–84 14.1
(13.4–14.9)
14.1
(13.1–15.2)
13.7
(12.7–14.8)
14.7
(13.7–15.8)
14.3
(13.4–15.3)
14.1
(13.1–15.2)
13.0
(12.1–14.0)
12.7
(11.9–13.6) (12. )
13.5
(12.5–14.5)
13.2
(12.2–14.2)
13.4
(12.5–14.5)
85 18.7
(17.7–19.8)
18.2
(16.8–19.9)
19.2
(17.6–20.8)
19.5
(17.9–21.1)
19.2
(17.8–20.8)
19.0
(17.5–20.5)
18.7
(17.2–20.2)
17.5
(16.0–19.0) (16. )
19.5
(17.9–21.1)
19.3
(17.8–20.9)
18.9
(17.3–20.5)
Sex
Female 15.3
(14.7–16.0)
14.8
(13.9–15.7)
15.3
(14.4–16.2)
15.4
(14.5–16.3)
15.2
(14.3–16.1)
15.3
(14.4–16.2)
14.5
(13.7–15.4)
14.1
(13.3–15.0) (13. )
15.6
(14.6–16.5)
14.5
(13.6–15.4)
14.8
(13.9–15.8)
Male 16.5
(15.7–17.3)
16.9
(15.8–18.1)
17.2
(16.1–18.4)
18.0
(16.8–19.2)
17.2
(16.1–18.4)
16.6
(15.5–17.7)
15.5
(14.5–16.6)
14.2
(13.2–15.2) (14. )
15.8
(14.8–16.9)
15.9
(14.8–17.0)
15.9
(14.8–17.0)
Race
Black 17.0
(15.3–18.9)
18.0
(15.4–20.6)
17.6
(15.1–20.3)
16.9
(14.7–19.5)
16.7
(14.5–19.2)
17.1
(14.8–19.6)
15.7
(13.6–18.1)
15.4
(13.3–17.7) (12. )
16.3
(14.2–18.8)
16.0
(13.8–18.4)
16.4
(14.2–18.9)
White 15.7
(15.2–16.3)
15.4
(14.6–16.2)
15.8
(15.0–16.6)
16.6
(15.8–17.4)
16.0
(15.2–16.7)
15.7
(14.9–16.5)
14.8
(14.1–15.4)
14.1
(13.4–14.8) (13. )
15.6
(14.8–16.4)
14.9
(14.2–15.7)
15.3
(14.5–16.1)
Other 15.1
(12.5–18.0)
15.0
(11.6–19.1)
17.5
(13.7–21.9)
14.3
(11.2–18.3)
16.5
(13.0–20.7)
16.7
(13.3–20.9)
17.9
(14.3–22.3)
14.7
(11.5–18.5) (11. )
15.1
(11.9–19.0)
16.9
(13.3–21.2)
13.3
(10.2–17.0)
Adjusted 1-year mortality rate, %y
Age, yrs
65–74 32.8
(31.6–34.1)
33.0
(31.2–34.7)
33.5
(31.7–35.5)
32.1
(30.5–33.9)
31.7
(30.0–33.5)
31.7
(30.0–33.2)
30.0
(28.6–31.8)
28.6
(37.0–30.3) (27. )
30.3
(28.8–32.1)
28.8
(27.3–30.5)
29.8
(28.1–31.5)
75–84 32.9
(31.9–34.0)
33.1
(31.5–34.6)
33.1
(31.5–34.4)
33.6
(32.0–34.8)
33.3
(32.0–34.8)
32.2
(30.9–34.6)
30.9
(29.4–32.2)
30.1
(28.7–31.5) (28. )
31.1
(29.7–32.7)
30.4
(29.4–32.5)
31.1
(29.7–32.7)
85 42.9
(41.6–44.3)
42.4
(40.3–44.3)
43.6
(41.6–45.7)
43.4
(41.4–45.5)
42.2
(41.1–44.1)
43.1
(41.1–45.0)
42.4
(40.3–44.3)
40.1
(38.1–41.9) (39. )
42.7
(40.9–44.8)
41.4
(39.3–43.4)
41.4
(39.5–43.4)
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2225data may have overestimated the number of cases of
endocarditis among older adults (22). However, results from
2 previous reports suggested good accuracy for detection of
endocarditis cases using the ICD-9-CM codes, with
reference to the revised Duke criteria (3,37). Fourth, the
most prominent change in the recent American Heart
Association guidelines was the restriction of indications for
antibiotic prophylaxis following dental procedures, which
would most possibly affect streptococcal endocarditis.
Therefore, analysis of the rates of all-cause endocarditis
might be unable to clearly detect a signal for change of
streptococcal endocarditis trends, if one existed. However,
the 2007 guidelines also eliminated endocarditis prophylaxis
recommendations for patients undergoing gastrointestinal,
hepatobiliary, and genitourinary procedures. Although
bacteremia following such procedures is not frequent, there
have been recent reports of nonstreptococcal bacteremia or
endocarditis following these procedures, suggesting some
risk (38,39). Therefore, we believe that lack of an increase in
hospitalization rates or mortality from all-cause endocarditis
is an important ﬁnding for surveillance investigation. Fifth,
our study determined the rates of hospitalization for
endocarditis, rather than its incidence. However, because
infective endocarditis requires initial hospitalization for
virtually all patients, particularly older adults, this limitation
is unlikely to fundamentally change our interpretation of the
observed trends.
Conclusions
Endocarditis continues to carry a high burden and mortality
rate among older adults. We did not detect an increase in the
rates of hospitalization for endocarditis or of adjusted
mortality after publication of the 2007 American Heart
Association guidelines, which recommended a restriction of
antibiotic prophylaxis.Acknowledgments
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